Clinical Trial Update: Open-Label Extension Study of Trofinetide for Rett Syndrome [Phase 3]

View source ↗

Summary

Open-label extension study of trofinetide for Rett syndrome was terminated (Phase 3), with results posted on 2024-09-27.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rett Syndrome

Drugs mentioned

• Daybree (trofinetide)

Snippet

Sponsor: ACADIA Pharmaceuticals Inc. | Conditions: Rett Syndrome | Phase 3 | Status: TERMINATED | Results posted: 2024-09-27